A small study published earlier this year in the New England Journal of Medicine showed that 92 per cent of patients with advanced colon and rectal cancers who had mismatch repair
defects responded to Merck & Co's immunotherapy drug Keytruda.
coli); MSH2, DNA mismatch repair
protein Msh2; MSH6, mutS homolog 6; PMS2, Mismatch repair
endonuclease PMS2; EPCAM, epithelial cell adhesion molecule.
Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair
proteins comprise a distinct clinicopathologic subset.
Both, the protein with truncation at 659th codon (resulting from insertion of stop codon) and the protein lacking internal 31 amino acids (through skipping of exon 17), have been shown to be inactive in mismatch repair
No data have been published demonstrating a relationship between mismatch repair
proteins and response to therapy in GC.
She and her colleagues recently uncovered deficiencies in mismatch repair
genes in some men with testicular failure, predominantly those with Sertoli-cell-only syndrome (Mol.
An in silico analysis suggested that most mismatch repair
We hypothesize that the lack of variation may be a result of a routs homologue, mtMSH, a mismatch repair
The findings concerning the genetic mutations, known as DNA mismatch repair
(MMR) genes, were published this month in the British Journal of Cancer and have sparked a race against time to save those who have inherited the condition.
One of the two non-resistant lines and its resistant clone were deficient in their DNA mismatch repair
systems, which results in genetic instability, increased susceptibility to neoplastic transformation, and greater development of chemoresistant cells.
Selection of endometrial carcinomas for DNA mismatch repair
protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair
The findings provide further confirmation that the Oncotype DX Recurrence Score (RS) results improve the ability to differentiate high recurrence risk disease from low, beyond conventional factors such as T-stage, mismatch repair
(MMR) status, nodes examined, grade and lymphovascular invasion.